Highlights on two decades with microbiota and inflammatory bowel disease from etiology to therapy

Colombel, 2019, AGA clinical practice update on functional gastrointestinal symptoms in patients with inflammatory bowel disease: expert review, Clin. Gastroenterol. Hepatol., 17, 380, 10.1016/j.cgh.2018.08.001 McDowell, 2022, Inflammatory bowel disease Axelrad, 2016, Inflammatory bowel disease and cancer: the role of inflammation, immunosuppression, and cancer treatment, World J. Gastroenterol., 22, 4794, 10.3748/wjg.v22.i20.4794 H.-J. Su, Y.-T. Chiu, C.-T. Chiu, Y.-C. Lin, C.-Y. Wang, J.-Y. Hsieh, S.-C. Wei, Inflammatory bowel disease and its treatment in 2018: Global and Taiwanese status updates, J. Formos. Med. Assoc. 118 (2019) 1083–1092. doi:https://doi.org/10.1016/j.jfma.2018.07.005. Tomasello, 2015 Mahapatro, 2021, Cytokine-mediated crosstalk between immune cells and epithelial cells in the gut, Cells., 10, 111, 10.3390/cells10010111 Solomon, 2010, The dextran sulphate sodium (DSS) model of colitis: an overview, Comp. Clin. Pathol., 19, 235, 10.1007/s00580-010-0979-4 Glassner, 2020, The microbiome and inflammatory bowel disease, J. Allergy Clin. Immunol., 145, 16, 10.1016/j.jaci.2019.11.003 Honda, 2012, The microbiome in infectious disease and inflammation, Annu. Rev. Immunol., 30, 759, 10.1146/annurev-immunol-020711-074937 Nishino, 2018, Analysis of endoscopic brush samples identified mucosa-associated dysbiosis in inflammatory bowel disease, J. Gastroenterol., 53, 95, 10.1007/s00535-017-1384-4 Fujimoto, 2013, Decreased abundance of Faecalibacterium prausnitzii in the gut microbiota of Crohn’s disease, J. Gastroenterol. Hepatol., 28, 613, 10.1111/jgh.12073 Sartor, 2017, Roles for intestinal Bacteria, viruses, and Fungi in pathogenesis of inflammatory bowel diseases and therapeutic approaches, Gastroenterology., 152, 327, 10.1053/j.gastro.2016.10.012 Nishida, 2018, Gut microbiota in the pathogenesis of inflammatory bowel disease, Clin. J. Gastroenterol., 11, 1, 10.1007/s12328-017-0813-5 Schrezenmeir, 2001, Probiotics, prebiotics, and synbiotics--approaching a definition, Am. J. Clin. Nutr., 73, 361S, 10.1093/ajcn/73.2.361s Cohen, 2019, Genetic factors and the intestinal microbiome guide development of microbe-based therapies for inflammatory bowel diseases, Gastroenterology., 156, 2174, 10.1053/j.gastro.2019.03.017 Ohashi, 2009, Health-beneficial effects of probiotics: its mode of action, Anim. Sci. J., 80, 361, 10.1111/j.1740-0929.2009.00645.x Sartor, 2008, Microbial influences in inflammatory bowel diseases, Gastroenterology., 134, 577, 10.1053/j.gastro.2007.11.059 Asquith, 2010, An innately dangerous balancing act: intestinal homeostasis, inflammation, and colitis-associated cancer, J. Exp. Med., 207, 1573, 10.1084/jem.20101330 Ananthakrishnan, 2018, Environmental triggers in IBD: a review of progress and evidence, Nat. Rev. Gastroenterol. Hepatol., 15, 39, 10.1038/nrgastro.2017.136 Hajj Hussein, 2008, Inflammatory bowel disease in rats: bacterial and chemical interaction, World J. Gastroenterol., 14, 4028, 10.3748/wjg.14.4028 Elangovan, 2020, When to use probiotics in luminal gastrointestinal disorders?, Curr. Opin. Clin. Nutr. Metab Care., 23, 336, 10.1097/MCO.0000000000000674 Abraham, 2017, Probiotics in inflammatory bowel disease, Gastroenterol. Clin. N. Am., 46, 769, 10.1016/j.gtc.2017.08.003 Hussein, 2012, Rat model of burn wound healing: effect of Botox, J. Biol. Regul. Homeost. Agents, 26, 389 Guandalini, 2019, Probiotics in the treatment of inflammatory bowel disease, Adv. Exp. Med. Biol., 1125, 101, 10.1007/5584_2018_319 Tomasello, 2017, The fingerprint of the human gastrointestinal tract microbiota: a hypothesis of molecular mapping, J. Biol. Regul. Homeost. Agents, 31, 245 Kim, 2017, A probiotic combination attenuates experimental colitis through inhibition of innate cytokine production, Benefic. Microbes, 8, 231, 10.3920/BM2016.0031 Friedrich, 2019, Cytokine networks in the pathophysiology of inflammatory bowel disease, Immunity., 50, 992, 10.1016/j.immuni.2019.03.017 Jurjus, 2004, Animal models of inflammatory bowel disease, J. Pharmacol. Toxicol. Methods, 50, 81, 10.1016/j.vascn.2003.12.002 Jurjus, 2007, Experimental inflammatory bowel disease in western diet fed rats, FASEB J., 21, A1123 Barada, 2007, Up-regulation of nerve growth factor and interleukin-10 in inflamed and non-inflamed intestinal segments in rats with experimental colitis, Cytokine., 37, 236, 10.1016/j.cyto.2007.04.005 Hussein, 2012, Enteropathogenic e.coli sustains iodoacetamide-induced ulcerative colitis-like colitis in rats: modulation of IL-1β, IL-6, TNF-α, COX-2, and apoptosisi, J. Biol. Regul. Homeost. Agents, 26, 515 Rappa, 2012, HSP-molecular chaperones in cancer biogenesis and tumor therapy: an overview, Anticancer Res., 32, 5139 Cappello, 2019, Hsp60 as a novel target in IBD management: a Prospect, Front. Pharmacol., 10, 10.3389/fphar.2019.00026 Marino Gammazza, 2019, Hsp60 in inflammatory disorders, 167, 10.1007/978-3-030-23154-5_12 Hajj Hussein, 2014, Estrogens control inflammation in experimental colitis, J. Biol. Regul. Homeost. Agents, 28, 213 Ec, 2009, Infliximab and the TNF-alpha system, Am. J. Physiol. Gastrointest. Liver Physiol., 296 Regueiro, 2016, PREVENT study group, infliximab reduces endoscopic, but not clinical, recurrence of Crohn’s disease after Ileocolonic resection, Gastroenterology., 150, 1568, 10.1053/j.gastro.2016.02.072 Kobayashi, 2005, Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract, Science., 307, 731, 10.1126/science.1104911 Petnicki-Ocwieja, 2009, Nod2 is required for the regulation of commensal microbiota in the intestine, Proc. Natl. Acad. Sci., 106, 15813, 10.1073/pnas.0907722106 Al Nabhani, 2016, Nod2 deficiency leads to a specific and transmissible mucosa-associated microbial Dysbiosis which is independent of the mucosal barrier defect, J. Crohn’s Colitis, 10, 1428, 10.1093/ecco-jcc/jjw095 Couturier-Maillard, 2013, NOD2-mediated dysbiosis predisposes mice to transmissible colitis and colorectal cancer, J. Clin. Invest., 123 Chu, 2016, Gene-microbiota interactions contribute to the pathogenesis of inflammatory bowel disease, Science., 352, 1116, 10.1126/science.aad9948 Bel, 2017, Paneth cells secrete lysozyme via secretory autophagy during bacterial infection of the intestine, Science., 357, 1047, 10.1126/science.aal4677 Lavoie, 2019, The Crohn’s disease polymorphism, ATG16L1 T300A, alters the gut microbiota and enhances the local Th1/Th17 response, ELife, 8, 10.7554/eLife.39982 Drummond, 2018, Human CARD9: a critical molecule of fungal immune surveillance, Front. Immunol., 9, 10.3389/fimmu.2018.01836 Gross, 2006, Card9 controls a non-TLR signalling pathway for innate anti-fungal immunity, Nature., 442, 651, 10.1038/nature04926 Yamamoto, 2014, Defect of CARD9 leads to impaired accumulation of gamma interferon-producing memory phenotype T cells in lungs and increased susceptibility to pulmonary infection with Cryptococcus neoformans, Infect. Immun., 82, 1606, 10.1128/IAI.01089-13 Jhingran, 2015, Compartment-specific and sequential role of MyD88 and CARD9 in chemokine induction and innate defense during respiratory fungal infection, PLoS Pathog., 11, 10.1371/journal.ppat.1004589 Sokol, 2013, Card9 mediates intestinal epithelial cell restitution, T-helper 17 responses, and control of bacterial infection in mice, Gastroenterology., 145, 591, 10.1053/j.gastro.2013.05.047 Jurjus, 2006, Morphological and biochemical alterations in the jejunum following iodoacetamide-induced colitis in rats, Can. J. Physiol. Pharmacol., 84, 1191, 10.1139/y06-069 Zhang, 2017, Cell surface-anchored syndecan-1 ameliorates intestinal inflammation and neutrophil transmigration in ulcerative colitis, J. Cell. Mol. Med., 21, 13, 10.1111/jcmm.12934 Dosh, 2021, The absence of Syndecan-1 leads to more inflammation in the mouse model of inflammatory bowel disease (IBD), FASEB J., 35, 10.1096/fasebj.2021.35.S1.03406 Andari, 2021, Epstein-Barr virus DNA exacerbates colitis symptoms in a mouse model of inflammatory bowel disease, Viruses., 13, 1272, 10.3390/v13071272 Porter, 2008, Infectious gastroenteritis and risk of developing inflammatory bowel disease, Gastroenterology., 135, 781, 10.1053/j.gastro.2008.05.081 Rodríguez, 2006, Acute gastroenteritis is followed by an increased risk of inflammatory bowel disease, Gastroenterology., 130, 1588, 10.1053/j.gastro.2006.02.004 Moossavi, 2018, The prebiotic and probiotic properties of human Milk: implications for infant immune development and pediatric asthma, Front. Pediatr., 6, 10.3389/fped.2018.00197 Goethel, 2019, Nod2 influences microbial resilience and susceptibility to colitis following antibiotic exposure, Mucosal Immunol., 12, 720, 10.1038/s41385-018-0128-y Kuenzig, 2016, Smoking influences the need for surgery in patients with the inflammatory bowel diseases: a systematic review and meta-analysis incorporating disease duration, BMC Gastroenterol., 16, 143, 10.1186/s12876-016-0555-8 Lee, 2018, Association between cigarette smoking status and composition of gut microbiota: population-based cross-sectional study, J. Clin. Med., 7, 282, 10.3390/jcm7090282 Bernstein, 2006, A population-based case control study of potential risk factors for IBD, Off. J. Am. Coll. Gastroenterol.|ACG, 101, 993, 10.1111/j.1572-0241.2006.00381.x Hou, 2011, Dietary intake and risk of developing inflammatory bowel disease: a systematic review of the literature, Off. J. Am. Coll. Gastroenterol.|ACG., 106, 563, 10.1038/ajg.2011.44 Stidham, 2018, Colorectal cancer in inflammatory bowel disease, Clin. Colon Rectal. Surg., 31, 168, 10.1055/s-0037-1602237 Worthen, 1998, The in vitro anti-tumor activity of some crude and purified components of blackseed, Nigella sativa L, Anticancer Res., 18, 1527 Gali-Muhtasib, 2008, Thymoquinone reduces mouse colon tumor cell invasion and inhibits tumor growth in murine colon cancer models, J. Cell. Mol. Med., 12, 330, 10.1111/j.1582-4934.2007.00095.x Nagle, 2006, Epigallocatechin-3-gallate (EGCG): chemical and biomedical perspectives, Phytochemistry., 67, 1849, 10.1016/j.phytochem.2006.06.020 Hussein, 2014, Epigallocatechin-3-gallate reduces mast cells activity TNF-α and NFKB in colitis by interrupting an inflammatory Cascade (MUC2P.827), J. Immunol., 192 Tomasello, 2016, Nutrition, oxidative stress and intestinal dysbiosis: influence of diet on gut microbiota in inflammatory bowel diseases, Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech Repub., 160, 461, 10.5507/bp.2016.052 Gerges Geagea, 2017, Tea catechins induce crosstalk between signaling pathways and stabilize mast cells in ulcerative colitis, J. Biol. Regul. Homeost. Agents, 31, 865 Carini, 2017, Colorectal cancer and inflammatory bowel diseases: effects of diet and antioxidants, J. Biol. Regul. Homeost. Agents, 31, 791 Aureli, 2011, Probiotics and health: an evidence-based review, Pharmacol. Res., 63, 366, 10.1016/j.phrs.2011.02.006 Bevivino, 2018, Advances in understanding the role of cytokines in inflammatory bowel disease, expert rev, Gastroenterol. Hepatol., 12, 907 Guan, 2017, Recent advances: the imbalance of cytokines in the pathogenesis of inflammatory bowel disease, Mediat. Inflamm., 2017, 4810258, 10.1155/2017/4810258 Plaza-Diaz, 2019, Mechanisms of action of probiotics, Adv. Nutr., 10, S49, 10.1093/advances/nmy063 Neurath, 2014, Cytokines in inflammatory bowel disease, Nat. Rev. Immunol., 14, 329, 10.1038/nri3661 Huidrom, 2020, Dysbiosis of gut microbiota and human diseases, J. Mahatma Gandhi Inst. Med. Sci., 25, 66, 10.4103/jmgims.jmgims_59_19 Ballini, 2019, Probiotics efficacy on oxidative stress values in inflammatory bowel disease: a randomized double-blinded placebo-controlled pilot study, Endocr Metab Immune Disord Drug Targets, 19, 373, 10.2174/1871530319666181221150352 Moller, 2015, Familial risk of inflammatory bowel disease: a population-based cohort study 1977-2011, Am. J. Gastroenterol., 110, 564, 10.1038/ajg.2015.50 Jakubczyk, 2020, The effectiveness of probiotics in the treatment of inflammatory bowel disease (IBD)-a critical review, Nutrients., 12, E1973, 10.3390/nu12071973 Dobre, 2018, Differential intestinal mucosa transcriptomic biomarkers for Crohn’s disease and ulcerative colitis, J Immunol Res, 2018, 9208274, 10.1155/2018/9208274 Satoh, 1997, New ulcerative colitis model induced by sulfhydryl blockers in rats and the effects of antiinflammatory drugs on the colitis, Jpn. J. Pharmacol., 73, 299, 10.1254/jjp.60.299 Jurjus, 2006, Characterization of an experimantal colitis model: bacterial and chemical induction, FASEB J., 20, A1265 G. Tomasello, IBD Malignancy and Oral Microbiota Analysis of the Literature. Intern J of CL Dentistry 2016.pdf, (n.d.). https://www.academia.edu/30761900/IBD_MALIGNANCY_AND_ORAL_MICROBIOTA_ANALYSIS_OF_THE_LITERATURE_INTERN_J_OF_CL_DENTISTRY_2016_pdf (accessed November 27, 2022). Hynes, 2002, Integrins: bidirectional, allosteric signaling machines, Cell., 110, 673, 10.1016/S0092-8674(02)00971-6 Dotan, 2020, The role of integrins in the pathogenesis of inflammatory bowel disease: approved and investigational anti-integrin therapies, Med. Res. Rev., 40, 245, 10.1002/med.21601 Hajj Hussein, 2013, Modulation of β2 and β3 integrins in experimental colitis induced by iodoacetamide and enteropathogenic E. coli, J. Biol. Regul. Homeost. Agents, 27 Jurjus, 2011, Modulation of Beta 2, Beta 3, and AlphavBeta3 Integrins in chronic experimental colitis induced by Iodoacetamide and Enteropathogenic E. coli, FASEB J., 25, 10.1096/fasebj.25.1_supplement.lb15 Lechuga, 1864, Disruption of the epithelial barrier during intestinal inflammation: quest for new molecules and mechanisms, Biochim. Biophys. Acta, Mol. Cell Res., 2017, 1183 Alhagamhmad, 2016, An overview of the bacterial contribution to Crohn disease pathogenesis, J. Med. Microbiol., 65, 1049, 10.1099/jmm.0.000331 Ganji-Arjenaki, 2018, Probiotics are a good choice in remission of inflammatory bowel diseases: a meta analysis and systematic review, J. Cell. Physiol., 233, 2091, 10.1002/jcp.25911 Dargahi, 2019, Immunomodulatory effects of probiotics: can they be used to treat allergies and autoimmune diseases?, Maturitas., 119, 25, 10.1016/j.maturitas.2018.11.002 Galdeano, 2006, The probiotic bacterium Lactobacillus casei induces activation of the gut mucosal immune system through innate immunity, Clin. Vaccine Immunol., 13, 219, 10.1128/CVI.13.2.219-226.2006 Yan, 2006, Probiotics as functional food in the treatment of diarrhea, Curr. Opin. Clin. Nutr. Metab Care., 9, 717, 10.1097/01.mco.0000247477.02650.51 Mattar, 2002, Probiotics up-regulate MUC-2 mucin gene expression in a Caco-2 cell-culture model, Pediatr. Surg. Int., 18, 586, 10.1007/s00383-002-0855-7 Möndel, 2009, Probiotic E. coli treatment mediates antimicrobial human beta-defensin synthesis and fecal excretion in humans, Mucosal Immunol., 2, 166, 10.1038/mi.2008.77 Amer, 2018, Probiotics and their use in inflammatory bowel disease, Altern. Ther. Health Med., 24, 16 Zhou, 2023, Fecal microbiota transplantation for induction of remission in Crohn’s disease: a systematic review and meta-analysis, Int. J. Color. Dis., 38, 1, 10.1007/s00384-023-04354-4 Cheng, 2021, Fecal microbiota transplantation for Crohn’s disease: a systematic review and meta-analysis, Tech Coloproctol., 25, 495, 10.1007/s10151-020-02395-3 Cheng, 2023, Fecal Microbiota Transplantation, Clin. Colon Rectal. Surg., 36, 151, 10.1055/s-0043-1760865 Kattar, 2020, Metformin and probiotics in the crosstalk between colitis-associated colorectal cancer and diabetes in mice, Cancers (Basel)., 12, E1857, 10.3390/cancers12071857 Llewellyn, 2017, Probiotic modulation of innate cell pathogen sensing and signaling events, Nutrients., 9, E1156, 10.3390/nu9101156 Geagea, 2019, A novel therapeutic approach to colorectal cancer in diabetes: role of metformin and rapamycin, Oncotarget., 10, 1284, 10.18632/oncotarget.26641 Ferreira, 2022, Relationship between intestinal microbiota, diet and biological systems: an integrated view, Crit. Rev. Food Sci. Nutr., 62, 1166, 10.1080/10408398.2020.1836605 Kaplan, 2021, The four epidemiological stages in the global evolution of inflammatory bowel disease, Nat. Rev. Gastroenterol. Hepatol., 18, 56, 10.1038/s41575-020-00360-x Darb Emamie, 2021, The effects of probiotics, prebiotics and synbiotics on the reduction of IBD complications, a periodic review during 2009-2020, J. Appl. Microbiol., 130, 1823, 10.1111/jam.14907 Park, 2018, A probiotic complex, rosavin, zinc, and prebiotics ameliorate intestinal inflammation in an acute colitis mouse model, J. Transl. Med., 16, 37, 10.1186/s12967-018-1410-1 Boirivant, 2007, The mechanism of action of probiotics, Curr. Opin. Gastroenterol., 23, 679, 10.1097/MOG.0b013e3282f0cffc Wilkins, 2017, Probiotics for gastrointestinal conditions: a summary of the evidence, Am. Fam. Physician, 96, 170 Eckburg, 2005, Diversity of the human intestinal microbial flora, Science., 308, 1635, 10.1126/science.1110591 Liu, 2021, The microbiome in inflammatory bowel diseases: from pathogenesis to therapy, Protein Cell., 12, 331, 10.1007/s13238-020-00745-3 Manuc, 2016, Recent insights into the molecular pathogenesis of Crohn’s disease: a review of emerging therapeutic targets, Clin. Exp. Gastroenterol., 9, 59 Jia, 2018, The clinical effects of probiotics for inflammatory bowel disease: a meta-analysis, Medicine (Baltimore), 97, 10.1097/MD.0000000000013792 Alex, 2009, Distinct cytokine patterns identified from multiplex profiles of murine DSS and TNBS-induced colitis, Inflamm. Bowel Dis., 15, 341, 10.1002/ibd.20753 Jess, 2020, Inflammatory bowel diseases increase risk of type 2 diabetes in a Nationwide cohort study, Clin. Gastroenterol. Hepatol., 18, 881, 10.1016/j.cgh.2019.07.052 Kim, 2019, Lactobacillus acidophilus suppresses intestinal inflammation by inhibiting endoplasmic reticulum stress, J. Gastroenterol. Hepatol., 34, 178, 10.1111/jgh.14362 Turpin, 2018, Determinants of IBD heritability: genes, bugs, and more, Inflamm. Bowel Dis., 24, 1133, 10.1093/ibd/izy085 Coqueiro, 2019, Probiotics for inflammatory bowel diseases: a promising adjuvant treatment, Int. J. Food Sci. Nutr., 70, 20, 10.1080/09637486.2018.1477123 Lorentz, 2022, Probiotics in the treatment of inflammatory bowel disease in adulthood: a systematic review, J. Gastrointestin Liver Dis., 31, 74, 10.15403/jgld-3936 Seto, 2012, Rapamycin and mTOR: a serendipitous discovery and implications for breast cancer, Clin. Transl. Med., 1, 29, 10.1186/2001-1326-1-29 Hosono, 2010, Metformin suppresses azoxymethane-induced colorectal aberrant crypt foci by activating AMP-activated protein kinase, Mol. Carcinog., 49, 662, 10.1002/mc.20637 Bellavia, 2014, Lactobacillus casei and bifidobacterium lactis supplementation reduces tissue damage of intestinal mucosa and liver after 2,4,6-trinitrobenzenesulfonic acid treatment in mice, J. Biol. Regul. Homeost. Agents, 28, 251 Palumbo, 2016, The long-term effects of probiotics in the therapy of ulcerative colitis: a clinical study, Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech Repub., 160, 372, 10.5507/bp.2016.044 Jurjus, 2017, Natural antioxidants and colorectal cancer: a new approach, FASEB J., 31 Youssef, 2018, Probiotics: in sickness and in health, Int. J. Recent Sci. Res. Qiu, 2022, The gut microbiota in inflammatory bowel disease, Front. Cell. Infect. Microbiol., 12, 10.3389/fcimb.2022.733992 Becker, 2023, Current evidence and clinical relevance of drug-microbiota interactions in inflammatory bowel disease, Front. Microbiol., 14, 10.3389/fmicb.2023.1107976 Saha, 2021, Long-term safety of fecal microbiota transplantation for recurrent Clostridioides difficile infection, Gastroenterology., 160, 1961, 10.1053/j.gastro.2021.01.010 Koppel, 2017, Chemical transformation of xenobiotics by the human gut microbiota, Science., 356, eaag2770, 10.1126/science.aag2770